Mr. Sam Brooks, president and chief executive officer of Renal Care Group, said, "I am very proud of our performance during the first half of the year. Clearly, we head into the remainder of 2001 with momentum working in our favor. Both financial and clinical quality results are strong, a tribute to all our associates who understand that our success depends on keeping these two critical components of our operating strategy in balance. Our ability to provide high-quality life sustaining dialysis services results in predictable recurring revenues and added value for our shareholders."

For the second quarter ended June 30, 2001, Renal Care Group's revenues increased 19% to $183.5 million compared with revenues of $154.2 million for the same period in 2000. Net income rose 18% to $18.4 million from $15.6 million in the same period last year, and earnings per share increased 12% to $0.37 compared with earnings per share of $0.33 in the same quarter of last year. For the quarter ended June 30, 2001, same-store treatment growth was 5.0% and same-store revenue growth was 13.4%.

For the six months ended June 30, 2001, revenues increased 18% to $358.2 million compared with revenues of $303.8 million for the same period in 2000. Net income rose 18% to $36.1 million from $30.5 million in the same period last year, and earnings per share increased 13% to $0.72 compared with earnings per share of $0.64 in the same quarter of last year. For the six months ended June 30, 2001, same-store treatment growth was 5.5% and same-store revenue growth was 12.7%.

Mr. Brooks added, "We continue to believe we will meet our financial goal of 15% growth in earnings per share for the remainder of this year as well as for the next two to four years. We see opportunity for improvement in existing markets, and we are on target for adding patients in 2001."

In closing, R. Dirk Allison, chief financial officer of the Company added, "In light of our results through June 30, 2001, we need to update two of our corporate goals for 2001. We are increasing our goal for revenues; it is now between $720 million and $730 million compared with our previous goal of between $690 million and $710 million. In addition, our goal for earnings before interest, depreciation, taxes and amortization (EBITDA) is now between $170 million and $180 million compared with our previous goal of between $165 million and $175 million. Renal Care Group intends to provide further updates if there are material changes in its corporate goals."

Renal Care Group will hold a conference call to discuss this press release on Wednesday, August 1, 2001, at 10:00 a.m. Central Daylight Time. A listen-only simulcast, as well as a 30-day replay, of the conference call to discuss this press release will be available online at the Company's website at www.renalcaregroup.com or www.streetevents.com.

Renal Care Group, Inc. is a dialysis services company that provides care to patients with kidney disease. The Company currently treats approximately 17,200 patients through 223 owned outpatient dialysis facilities, in addition to providing acute dialysis services to more than 115 hospitals. Over 5,000 associates provide services across the Company's 25-state network.

Certain statements in this press release, particularly the statements of Mr. Brooks and Mr. Allison, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Renal Care Group to differ materially from those expressed in or implied by the forward-looking statements, including risks related to: compliance with health care and other applicable laws; the integration of acquired companies; changes in the Medicare and Medicaid programs; risks related to EPO; payment reductions by private insurers, hospitals or managed care organizations; and changes in the health care delivery, financing or reimbursement systems. These and other factors affecting the company are discussed in more detail in Renal Care Group's reports filed with the Securities and Exchange Commission, including without limitation Renal Care Group's annual report on Form 10-K for the year ended December 31, 2000 and its quarterly report on Form 10-Q for the quarter ending March 31, 2001. Copies of these filings are available from Renal Care Group upon request.

                        RENAL CARE GROUP, INC.
             Unaudited Consolidated Statements of Earnings
                 (In thousands, except per share data)

                             Three Months Ended     Six Months Ended
                                 June 30,               June 30,
                          --------------------  ----------------------
                             2001       2000        2001       2000
                          ---------  ---------  ----------  ----------
Net revenue               $ 183,455  $ 154,152  $  358,233  $  303,809
Operating costs
 and expenses:
  Patient care costs        118,803     99,415     232,131     194,854
  General and
   administrative expense    15,778     13,950      30,781      28,695
  Provision for
   doubtful accounts          4,870      4,156       9,670       8,253
  Depreciation and
   amortization               9,296      7,808      18,148      15,580
                          ---------  ---------  ----------  ----------
     Total cost
      and expenses          148,747    125,329     290,730     247,382

Income from operations       34,708     28,823      67,503      56,427
Interest expense              1,274      1,366       2,273       2,862
                          ---------  ---------  ----------  ----------
Income before merger
 costs, minority interest
 and taxes                   33,434     27,457      65,230      53,565
Minority interest             3,722      2,258       6,852       4,427
                          ---------  ---------  ----------  ----------
Net income before merger
 costs and income taxes      29,712     25,199      58,378      49,138
Income taxes                 11,351      9,584      22,303      18,675
                          ---------  ---------  ----------  ----------

Net income before
 merger costs             $  18,361  $  15,615  $   36,075  $   30,463
                          =========  =========  ==========  ==========

Diluted earnings per
 share before merger
 costs                    $    0.37  $    0.33  $     0.72  $     0.64
                          =========  =========  ==========  ==========

Net income after
 merger costs             $  18,361  $  11,949  $   36,075  $   26,797
                          =========  =========  ==========  ==========

Diluted earnings per
 share after merger costs $    0.37  $    0.25  $     0.72  $     0.56
                          =========  =========  ==========  ==========

Weighted average shares
 outstanding                 50,046     47,800      49,828      47,600
                          =========  =========  ==========  ==========

Patients                     17,237     15,866      17,237      15,866
Treatments                  657,328    599,253   1,301,474   1,188,549

Same-Store
 Treatment Growth               5.0%       7.3%        5.5%        7.8%
Same-Store
 Revenue Growth                13.4%      13.2%       12.7%       13.0%

Patient Revenue
 Per Treatment            $     275  $     249  $      271  $      248


                        RENAL CARE GROUP, INC.
                      Consolidated Balance Sheets
                            (In thousands)

                                                  June 30,    Dec. 31,
                                                    2001        2000
                                                  --------    --------
ASSETS:                                         (Unaudited)

Current Assets:
 Cash and cash equivalents                        $ 32,191    $ 29,902
 Accounts receivable, net                          126,747     122,816
 Other current assets                               67,571      63,619
                                                  --------    --------
     Total current assets                          226,509     216,337

Property, plant and equipment, net                 152,485     139,573
Intangibles and other assets, net                  236,933     232,470
                                                  --------    --------

     TOTAL ASSETS                                 $615,927    $588,380
                                                  ========    ========

                LIABILITIES AND STOCKHOLDERS' EQUITY:

Total current liabilities                         $101,354    $100,592
Long-term debt                                      24,069      58,316
Other liabilities                                   35,045      35,350
                                                  --------    --------
     Total liabilities                             160,468     194,258
                                                  --------    --------

Stockholders' equity:
 Common stock, $.01 par value, 90,000 shares
  authorized, 48,397 and 47,091 shares issued
  and outstanding, respectively                        484         471
 Additional paid-in capital                        259,987     234,738
 Retained earnings                                 194,988     158,913
                                                  --------    --------
     Total stockholders' equity                    455,459     394,122
                                                  --------    --------

     TOTAL LIABILITIES AND
      STOCKHOLDERS' EQUITY                        $615,927    $588,380
                                                  ========    ========